Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications.

Abstract excerpt

INTRODUCTION: Biliary tract carcinoma (BTC) is a heterogenous group of aggressive hepatic malignancies, second to hepatocellular carcinoma per prevalence. Despite clinical research advancement, the overall 5-year survival rate is just above 2%. With the identification of somatic core mutations in half of cholangiocarcinomas. In the intrahepatic subtype (iCCA), it is possible to target mutational pathways of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bile Duct Neoplasms
• Share to Bile Ducts, Intrahepatic